T issue hypoxia and ischemia are known to initiate a series of events that lead to the development of collateral blood vessels 1 in a process referred to as compensatory angiogenesis. 2 However, the cellular and molecular mechanisms underlying compensatory angiogenesis have been only partially elucidated. 2 Potential mediators of compensatory angiogenesis include vascular endothelial growth factor (VEGF), 3 basic fibroblast growth factor (bFGF), 4 insulin-like growth factor-I (IGF-I), 5 and nucleosides such as adenosine. 6 Adenosine, the subject of the present study, has been proposed to be a factor that links altered cellular metabolism caused by oxygen deprivation to the formation of new capillaries. [7] [8] [9] This proposed role of adenosine is based on the observation that this nucleoside is released in increased amounts by hypoxic and/or ischemic cells and promotes proliferation of endothelial cells. 9 -11 Consistent with this hypothesis, adenosine and adenosine analogs have been reported to affect a number of steps involved in angiogenesis, including endothelial cell proliferation, 8, [12] [13] [14] migration, 12, 15, 16 and blood vessel formation in various vascular beds. 15, 17 Adenosine can interact with at least 4 subtypes of G proteincoupled receptors, designated A 1 , A 2A , A 2B , and A 3 . 18 These receptor subtypes are encoded by distinct genes and can, for the most part, be differentiated on the basis of their affinities for selected agonists and antagonists. 19, 20 A 1 and A 3 adenosine receptors are coupled to pertussis toxin-sensitive inhibitory G proteins that inhibit adenylyl cyclase activity, whereas A 2A (high-affinity) and A 2B (low-affinity) adenosine receptors are coupled to cholera toxin-sensitive G proteins that stimulate adenylyl cyclase activity. 21 In most cell types and organ systems, activation of A 1 adenosine receptors results in decreased work, and therefore, reduced O 2 consumption. Activation of A 2A adenosine receptors, on the other hand, increases O 2 supply by causing vasodilation. 22 Thus, adenosine is an ideal metabolite to respond to imbalances between O 2 supply and demand. In the retina, hypoxia is followed by compensatory angiogenesis, which is detrimental and results in aberrant blood vessels that are friable and prone to bleeding. 23 VEGF is a potent endothelial mitogen, induced by hypoxia and hyperglycemia, and has been shown to be an important factor in ischemic ocular neovascularization. 24 -26 VEGF causes hyperpermeability of blood vessels, which is observed in both nonproliferative and proliferative diabetic retinopathy. VEGF acts through 2 receptors, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), both of which are tyrosine kinases. VEGF signaling occurs through tyrosine phosphorylation of phospholipase C (PLC) and phosphatidylinositol 3Ј-kinase. 27, 28 The effects of VEGF are also mediated by activation of protein kinase C (PKC) to induce membrane translocation of PKC isoforms, especially the ␤-isoform of the enzyme. 25 VEGFR-1 mediates the permeability effects associated with VEGF, whereas VEGFR-2 mediates the proliferative effects of VEGF. Elevated levels of VEGF have been detected in vitreous humor of diabetic patients with proliferative retinopathy. 25 More importantly, in animal models of retinal neovascularization, inhibition of VEGF blocks neovascularization. 29 Other growth factors have been implicated in ocular angiogenesis, including bFGF 30 and IGF-I. 31 The experiments described were performed test the hypothesis that adenosine regulates expression of the angiogenic growth factor VEGF and to determine the adenosine receptor subtype that mediates the effect of the nucleoside in retinal endothelial cells of human origin.
Materials and Methods
5Ј-N-ethylcarboxamidoadenosine (NECA), 2-p-(2-carboxyethyl) phenethylamino-NECA (CGS21680), N 6 -cyclopentyladenosine (CPA), xanthine amine congener (XAC), and 8-cyclopentyl-1,3-dipropylxanthine (CPX) were from Research Biochemicals, Inc. 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-E)-1,2,4-trizolo(1,5-c) pyrimidine (SCH58261) was a gift from ScheringPlough Research Institute. Rabbit anti-human VEGF was from Peprotech. Antibodies and conjugates for immunofluorescence were as follows. Chicken anti-human A 2B adenosine receptor, 32 FITCconjugated rabbit anti-chicken IgG, and nonimmune sera were from Sigma-Aldrich. Sense and antisense oligonucleotides corresponding to either VEGF or A 2B adenosine receptor sequences were synthesized by Life Technologies. The sequences were chosen from the region proximal to and including the start codon using published sequence information for these genes. The antisense sequences are as follows: VEGF, AGACAGCAGAAAGTTCATGG, and A 2B adenosine receptor, CAGCGCGTCCTGTGTCTCCAGCAGCATGG. Sense sequences are the complement of the antisense sequences shown.
Human retinal endothelial cells (HRECs) were prepared and maintained as previously described. 33 Cells in passages 3 to 6 were used for the studies. The identity of HRECs was validated by demonstrating endothelial cell incorporation of fluorescently labeled acetylated LDL and by fluorescence-activated cell sorting analysis as previously described. 33 For all experiments, cells were starved of serum overnight and then incubated with adenosine deaminase type III (2 U/mL, Sigma-Aldrich) for 20 minutes before test agents were added. Adenosine receptor agonists and antagonists were added at concentrations ranging from 5 nmol/L up to 100 mol/L in serumfree medium containing adenosine deaminase type III and then incubated for additional times as indicated in specific results. cAMP was measured in response to adenosine receptor agonists and/or antagonists as described. 34 Conditioned medium was used to measure changes in VEGF protein in response to adenosine receptor agonists and/or antagonists using an ELISA kit (R&D Systems, Inc).
HREC proliferation was determined by measuring DNA synthesis via colorimetric detection of bromodeoxyuridine (BrdU) incorporation using a kit (Roche Molecular Biochemicals), and also by changes in cell number. BrdU incorporation was also used to measure the effect of anti-VEGF antibody on adenosine receptor agonist-induced HREC proliferation. The potential reduction of VEGF synthesis induced by adenosine receptor agonist was tested by ELISA after inclusion of antisense oligonucleotides directed against mRNA for either A 2B adenosine receptor or VEGF. Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), using a competitive synthetic multiplex template as described previously, 35 was performed to measure changes in mRNA after treatment with adenosine receptor agonists and/or antagonists. Immunofluorescent confocal microscopy was used as described 36 to demonstrate both the presence of A 2B adenosine receptors and uptake of fluorescencelabeled acetylated LDL in HRECs grown on multichamber glass slides (Nalge Nunc International).
Statistical Analysis
Comparisons between treatment groups (as described in the figure legends) were analyzed by 1-way ANOVA followed by the Bonferroni t test. Data are expressed as meanϮSEM. Values of PϽ0.05 were considered statistically significant.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
The nonselective adenosine receptor agonist NECA, after 48 hours of exposure, induced a concentration-dependent increase in DNA synthesis by HRECs, as indicated by BrdU incorporation ( Figure 1A ). In contrast, neither the A 2A adenosine receptor agonist CGS21680 (10 nmol/L to 10 mol/L) nor the A 1 adenosine receptor agonist CPA (10 nmol/L to 10 mol/L) increased BrdU incorporation by HRECs ( Figure  1A ). The addition of the adenosine receptor antagonist XAC completely prevented NECA-stimulated BrdU incorporation ( Figure 1B ). In contrast, neither the selective A 1 adenosine receptor antagonist CPX (20 nmol/L) nor the selective A 2A adenosine receptor antagonist SCH58261 (60 nmol/L) attenuated the stimulatory effect of NECA on BrdU incorporation by HRECs ( Figure 1B) .
The data for cell counts were consistent with those for BrdU incorporation. Treatment with NECA for 48 hours resulted in a concentration-dependent increase in HREC number, whereas neither CGS21680 nor CPA caused an increase in cell number ( Figure 2A ). Of the 3 adenosine receptor antagonists tested, only XAC (10 mol/L) significantly inhibited the increase in cell number induced by 10 mol/L NECA ( Figure 2B ).
cAMP Accumulation
To obtain evidence for the presence of the A 2B adenosine receptors in HRECs, we performed assays for cAMP content in intact HRECs after treatment of cells with adenosine receptor agonists and antagonists. The nonselective adenosine receptor agonist NECA increased the cAMP content of HRECs in a concentration-dependent manner ( Figure 3A) , with an EC 50 value of 24 mol/L. In contrast, the selective high-affinity A 2A adenosine receptor agonist CGS21680 (at concentrations up to 100 mol/L) had no significant effect on cAMP content of HRECs ( Figure 3A ). The effect of selective A 1 and A 2A adenosine receptor antagonists on NECA-induced accumulation of cAMP was also examined. NECA (10 mol/L)- 
Quantification of VEGF, IGF-I, and bFGF mRNA in HRECs
To determine whether NECA stimulates angiogenic growth factor mRNA expression in HRECs, total mRNA from HRECs exposed to NECA was subjected to quantitative RT-PCR. Treatment of HRECs with NECA (10 nmol/L to 10 mol/L) for 2 hours induced a concentration-dependent increase in expression of mRNA for VEGF by up to 4.6-fold (from 0.4ϫ10 6 to 1.85ϫ10 6 copies/g RNA), compared with untreated control cells. After 8 hours of exposure to NECA, cell mRNA levels for VEGF in cells treated with NECA had returned to baseline. HRECs were also treated with the A 2A adenosine receptor agonist, CGS21680 (10 nmol/L to 10 mol/L), and the A 1 adenosine receptor agonist, CPA (10 nmol/L to 10 mol/L). In contrast to NECA, neither CGS21680 nor CPA caused a significant change in VEGF mRNA expression (data not shown).
The increase in mRNA for VEGF caused by 10 mol/L NECA was not attenuated significantly either by the selective A 2A hours of exposure (from 30ϫ10 3 copies/g RNA to 65ϫ10
3 copies/g RNA) and 11.7-fold (350ϫ10 3 copies/g RNA) after 8 hours of exposure to NECA. Similarly, bFGF mRNA increased 3.7-fold after 2 hours of exposure (from 2ϫ10 3 copies/g RNA to 7.4ϫ10 3 copies/g RNA) and 11.4-fold (22.8ϫ10 3 copies/g RNA) after 8 hours of exposure to NECA.
Quantification of VEGF Protein in Conditioned Medium
To determine whether the increase in VEGF mRNA expression resulted in increased protein levels, VEGF was measured in conditioned medium after 8 hours of exposure to NECA, in the presence or absence of adenosine receptor antagonists ( Figure 5 ). NECA increased VEGF protein, but neither the A 1 adenosine receptor agonist CPA (not shown) nor the A 2A adenosine receptor agonist CGS21680 caused an increase in VEGF protein ( Figure 5 ). The increase in VEGF protein caused by NECA was not attenuated by either the selective 
Effect of Anti-VEGF Antibody on NECA-Induced HREC Proliferation
Incubation with 10 ng/mL VEGF resulted in BrdU incorporation to a level approximating that induced by normal growth medium. The anti-VEGF antibody at 100 ng/mL significantly reduced DNA synthesis induced by VEGF ( Figure 6 ). Incubation with NECA (10 mol/L) increased DNA synthesis to levels comparable with that induced by normal growth medium. The addition of anti-VEGF antibody resulted in a decrease in NECA-induced BrdU incorporation, which was statistically significant at the highest concentration of antibody used ( Figure 6 ). Similar results were observed at either 24 or 48 hours of exposure to the test agents.
Effect of Antisense Oligonucleotides on VEGF Induction by NECA
Both A 2B adenosine receptor and VEGF antisense oligonucleotides caused a significant decrease of VEGF in the conditioned medium after NECA exposure (Figure 7 ). This effect was most pronounced for the receptor antisense oligonucleotide with 10 nmol/L NECA, but it was evident for all concentrations of NECA tested. The VEGF antisense oligonucleotide also caused a decrease in secreted VEGF in response to NECA, although not to the same magnitude as that observed with the A 2B adenosine receptor antisense.
Immunofluorescence
Analysis of acetylated LDL uptake indicates that the cells are indeed of endothelial origin ( Figure 8A ). These results were confirmed by immunofluorescent labeling with antibody to coagulation factor VIII (data not shown). Labeling with A 2B adenosine receptor antibody clearly demonstrated that the tested cells express the A 2B receptor subtype ( Figure 8B and 8C) .
Discussion
In this report, we demonstrate that the nonselective adenosine receptor agonist NECA, but neither the A 2A adenosine receptor agonist CGS21680 nor the A 1 adenosine receptor agonist CPA, stimulates HREC DNA synthesis, proliferation, and cAMP accumulation. Furthermore, neither the selective A 2A adenosine receptor antagonist SCH58261 nor the A 1 adenosine receptor selective antagonist CPX attenuated significantly the effects of NECA. Only the nonselective adenosine receptor antagonist XAC reduced significantly the NECAmediated increase of DNA synthesis, cell proliferation, cAMP content, and VEGF synthesis. The A 2B adenosine receptor, which we localized in HRECs using a specific antibody, is the predominant adenosine receptor subtype responsible for mediating the actions of NECA. Equally or more importantly, the addition of VEGF antibody decreased significantly NECA-induced BrdU incorporation. This finding provides strong evidence that VEGF plays a major role in mediating the mitogenic effect of NECA and, presumably, the natural ligand adenosine. We also demonstrated a significant increase in expression of mRNA for both IGF-I and bFGF after 8 hours of exposure to NECA. Thus, our data also raise the possibility that, in addition to VEGF, IGF-I and 
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bFGF may contribute in part to the proliferative effect of NECA.
In HRECs, NECA caused a concentration-dependent increase in VEGF mRNA as well as an increase in secreted VEGF protein that was blocked by an antisense oligonucleotide complementary to A 2B adenosine receptor mRNA. In contrast, neither the A 2A agonist CGS21680 nor the A 1 agonist CPA affected the expression either of VEGF mRNA or protein, ruling out a role for either A 2A or A 1 adenosine receptors in mediating increased VEGF expression, increased BrdU incorporation, and cell proliferation. NECA-induced increases in expression of both VEGF mRNA and protein by HRECs were blocked by the nonselective adenosine receptor antagonist XAC, whereas the A 1 -and A 2A -selective adenosine receptor antagonists CPX (20 nmol/L) and SCH58261 (60 nmol/L), respectively, did not attenuate these increases. The antagonists CPX and SCH58261 were used at concentrations at which their selectivity for A 1 and A 2A receptors has been demonstrated in cardiovascular preparations. 18, 37, 38 On the other hand, XAC was used at a concentration (10 mol/L) that should be sufficient to antagonize effectively A 1 , A 2A , A 2B , and possibly the A 3 receptor-mediated responses.
Hence, the evidence supporting the role of A 2B adenosine receptors as the adenosine receptor subtype that mediates the effects of NECA reported here can be summarized as follows: (1) A 2B receptors were localized in HRECs using immunofluorescence microscopy with the A 2B antibody; (2) antisense oligonucleotides homologous to the A 2B receptor blocked NECA-stimulated VEGF production; (3) neither the A 1 nor the A 2A receptor agonists had any effect on BrdU incorporation, cell proliferation, or cAMP production; (4) neither the A 1 nor the A 2A antagonists, used at the concentration at which they are selective for their receptor subtype, antagonized the effects of NECA; and (5) the nonselective but potent A 2B antagonist XAC used at high concentrations significantly attenuated the effects of NECA.
Taken together, the data support the hypothesis that the A 2B adenosine receptor, but neither the A 1 nor the A 2A receptor, is responsible for mediating the actions of NECA on cAMP accumulation and VEGF synthesis in cultured HRECs. The results of our studies do not rule out a possible role of A 3 receptor in mediating the effects of NECA. However, this is unlikely, because the affinity (K i ) of XAC for the A 3 adenosine receptor is 29 mol/L, which is higher than the concentration (10 mol/L) used in our studies. 37, 39 Our conclusion that the A 2B receptor is the most likely adenosine receptor subtype that mediates the effects of NECA-and presumably adenosine-on HRECs differs from that reported by Takagi et al. 40, 41 These investigators, using retinal endothelial cells of bovine origin, concluded that the proliferative action of adenosine is mediated by A 2A receptor. Takagi et al 40 also reported that acute hypoxia causes a decline in KDR/Flk mRNA levels as well as VEGF binding sites on the cell surface. On the other hand, chronic hypoxia was associated with increased KDR/Flk message levels. 40 More importantly, Takagi et al 41 also reported that the endogenous adenosine released by hypoxic bovine retinal endothelial cells was sufficient to stimulate VEGF message expression. Species differences and passage number may account for differences in the observed adenosine receptor subtype in retinal endothelial cells. Furthermore, distinct adenosine receptor subtypes may mediate the proliferative effects of adenosine in endothelial cells from different vascular beds, even within the same species.
Protein kinase A and members of the mitogen-activated protein kinase, family such as extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) are potential mediators of adenosine-mediated cell proliferation. [42] [43] [44] Activation of the A 2B adenosine receptor results in cAMP generation via G s . A 2 receptor activation and stimulation of adenylyl cyclase/protein kinase A pathways can either activate 11 or inhibit [45] [46] [47] growth factor-stimulated ERK activity.
A 2B adenosine receptor signaling through G q/11 also results in increased levels of ERK. 42 Therefore, A 2B receptor stimulation of G q/11 , PLC, and PKC may synergize with or potentiate the effects of traditional tyrosine kinase- coupled growth factors, 48, 49 either through c-src-dependent activation of ERK or through PKC-dependent, srcindependent, pathways. Because forskolin-mediated adenylyl cyclase activity does not activate VEGF expression in endothelial cells, 50 G q/11 -and PKC-mediated activation of ERK may contribute to activation of transcription factors and lead to the induction of message for VEGF. 51 Thus, A 2B receptor activation can mediate proliferation by inducing growth factor synthesis and through stimulation of G q/11 , PLC, and PKC pathways. Angiogenesis is a compensatory mechanism in response to insufficient tissue oxygenation. 2 In the retina of diabetic individuals, homeostatic abnormalities lead to retinal nonperfusion and subsequent ischemia. 52 Ischemia leads to new vessel formation and disruption of the normal retinal vasculature, the hallmarks of proliferative diabetic retinopathy. 23 Our findings raise the possibility that selective A 2B adenosine receptor antagonists could be used as a novel therapeutic approach to block the inciting events leading to aberrant angiogenesis in proliferative diabetic retinopathy. Pharmacological modulation of the neovascular response in a nondestructive manner should have significant advantages over current therapeutic approaches.
By blocking the A 2B adenosine receptor, the action of adenosine to induce the growth factor cascade may be inhibited, and blocking the A 2B adenosine receptor may attenuate aberrant cellular proliferation. In summary, our results provide strong evidence that the proliferative effect of adenosine on HRECs is caused by increased expression of VEGF and probably other growth factors, and this effect is mediated by the A 2B adenosine receptor.
were used as a negative control and showed no evidence of acetylated LDL uptake (data not shown). B, Confocal image of HRECs at Ϸ50% confluence reacted with FITC-conjugated rabbit anti-chicken Ab showing nonspecific binding of this antibody. Magnification, ϫ60. C, Confocal image of HRECs at Ϸ50% confluence reacted first with AF5 chicken anti-A 2B adenosine receptor Ab, followed by FITC-conjugated rabbit antichicken Ab, demonstrating specific reactivity of the cells to the anti-A 2B receptor antibody. Magnification, ϫ60. 
